Satoshi Hashigaki

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

Kenji Tamura, Hirofumi Mukai, Yoichi Naito et al. · Cancer Science · 2016 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

Hirofumi Mukai, Chikako Shimizu, Norikazu Masuda et al. · International Journal of Clinical Oncology · 2018 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong‐Wan Kim, Yi‐Long Wu et al. · Cancer Research and Treatment · 2017 · 60 citations · Full text

Medicine, Oncology, Pharmacology +14

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

Norikazu Masuda, Kenichi Inoue, Rikiya Nakamura et al. · International Journal of Clinical Oncology · 2018 · 58 citations · Full text

Medicine, Oncology, Pharmacology +14

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

Hiroji Iwata, Norikazu Masuda, Shinji Ohno et al. · Breast Cancer Research and Treatment · 2013 · 57 citations · Full text

Pharmacy, Oncology, Pharmacology +17